New drug aims to reignite immune attack on Hard-to-Treat cancers
NCT ID NCT04471987
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new drug called IL12-L19L19 (Dodekin) in 80 adults with advanced or metastatic solid tumors that have stopped responding to standard immunotherapy. The drug combines an antibody with an immune-boosting protein to target and attack cancer cells. The main goals are to check safety, find the right dose, and look for early signs that the drug might shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IL12-L19L19 (Dodekin), a drug that combines an antibody with a protein to boost the immune system against tumors
What this could lead to
If successful, this could lead to a new treatment option for patients with advanced solid tumors who have stopped responding to standard immunotherapy.
What could go wrong
This is an early Phase I trial with only 80 participants, focused on safety and dosing. It is too small to prove effectiveness, and side effects or lack of benefit are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Azienda Ospedaliero-Universitaria San Luigi Gonzaga
NOT_YET_RECRUITINGOrbassano, Italy
Contact
Contact
-
Fondazione IRCCS Istituto Nazionale dei Tumori
RECRUITINGMilan, 20133, Italy
Contact
Contact
-
Geneva University Hospital, Oncology Department
RECRUITINGGeneva, Canton of Geneva, 1211, Switzerland
Contact
Contact
-
IEO - Istituto Europeo di Oncologia
RECRUITINGMilan, Italy, Italy
Contact
Contact
-
Insel Gruppe AG
RECRUITINGBern, Canton of Bern, 3010, Switzerland
Contact
Contact
-
Oncology Institute of Southern Switzerland
RECRUITINGBellinzona, 6500, Switzerland
Contact
Contact
-
Universitaetsklinik Hamburg-Eppendorf
RECRUITINGHamburg, Free and Hanseatic City of Hamburg, Germany
Contact
Contact
-
Universitätsklinikum Heidelberg, Nationalen Centrum für Tumorerkrankungen (NCT), Dermatoonkologie
RECRUITINGHeidelberg, Heidelberg, 69120, Germany
Contact
Contact
-
Universitätsklinikum Leipzig, Klinik für Dermatologie, Venerologie und Allergologie
RECRUITINGLeipzig, Leipzig, 04103, Germany
Contact
Contact
-
Universitätsklinikum Tübingen, Klinik für Innere Medizin VIII Medizinische Onkologie und Pneumologie
RECRUITINGTübingen, 72076, Germany
Contact
Contact
-
Universitätsspital Basel
RECRUITINGBasel, Basel, CH-4031, Switzerland
Contact
Contact